<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-60508</identifier>
<setSpec>0213-005X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Toxicogenetics of antiretroviral treatment (1): Lipodystrophy, metabolic perturbations and atherosclerosis</dc:title>
<dc:description xml:lang="en">Among the adverse effects attributed to antiretroviral therapy, one of the most striking is probably the appearance of the lipodystrophy syndrome and its associated metabolic derangements, given its potential long-term effect as a cardiovascular risk factor. Since not all patients who receive antiretroviral drugs experience these adverse effects, a host genetic predisposition has been postulated. However, currently available data on this issue is inconclusive and preliminary. It has been consistently demonstrated that polymorphisms in the genes that encode for apolipoproteins A5, C3 and E, for the cholesterol ester transporter proteins (CETP), and in the ATP binding cassette type A1 (ABCA1) influence the development of dyslipidemia in patients treated with antiretroviral drugs, particularly if the therapeutic regimen includes protease inhibitors. Data on the effect of polymorphisms in the sterol regulatory ester binding protein type 1 (SREBP1) are inconsistent. The effect of mitochondrial DNA mutations on the risk of lipodystrophy has been assessed, with inconclusive data. No polymorphisms in the lamin A gene have been detected. Investigations have assessed the effect of diverse polymorphisms in the genes that encode for several proinflammatory cytokines such as tumour necrosis factor alpha (TNF-¦Á), interleukin-1-beta (IL-1¦Â) and interleukin-6 (IL-6). The results show inconsistent data in the case of TNF-¦Á, no association in the case of IL-6, and preliminary positive associations in IL-1¦Â. In contrast, polymorphisms in the genes encoding for stromal derived factor 1 (SDF-1) and for monocyte chemoattractant protein 1 (MCP-1) have been shown to influence the development of subclinical atherosclerosis in HIV-1-infected patients treated with antiretroviral drugs(AU)</dc:description>
<dc:creator>Guti¨¦rrez Maci¨¢, M. del Mar</dc:creator>
<dc:creator>Mateo Garc¨ªa, M. Gracia</dc:creator>
<dc:creator>Domingo Pedrol, Pere</dc:creator>
<dc:creator>Vidal Marsal, Francesc</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Entre los efectos adversos del tratamiento antirretroviral, probablemente el m¨¢s trascendente sea la toxicidad metab¨®lica y sobre el tejido adiposo por sus eventuales consecuencias a largo plazo en t¨¦rminos de riesgo cadiovascular. Dado que no todos los pacientes tratados con f¨¢rmacos antirretrovirales la presentan, se ha postulado que debe existir una predisposici¨®n gen¨¦tica. La informaci¨®n actualmente disponible es, a menudo, no concordante. Se ha demostrado de forma consistente que los polimorfismos en los genes que codifican para las apolipoprote¨ªnas A5, C3 y E, para las prote¨ªnas transportadoras de ¨¦steres de colesterol (CETP), y en el cassette de enlace a ATP tipo A1 (ABCA1), modulan la generaci¨®n de la dislipidemia secundaria al tratamiento antirretroviral, especialmente si ¨¦ste contiene inhibidores de la proteasa (IP). En cuanto a los polimorfismos de la prote¨ªna de uni¨®n al elemento regulador de esteroles tipo 1 (SREBP1), no existen evidencias concordantes. En el caso de la redistribuci¨®n de la grasa corporal o lipodistrofia, se ha estudiado si mutaciones en el ADN mitocondrial modulan el riesgo de aparici¨®n, con resultados no concluyentes. Se ha descartado de forma rotunda la existencia de mutaciones en el gen de la lamina. Se han investigado los polimorfismos de genes que codifican para citocinas proinflamatorias, incluyendo el factor de necrosis tumoral alfa (TNF-¦Á), la interleucina 1 beta (IL-1¦Â) y la interleucina 6 (IL-6), con evidencias contradictorias en el caso del TNF-¦Á, negativas en el caso de la IL-6 y datos que sugieren una asociaci¨®n positiva en el caso de la IL-1¦Â. Por otra parte, los polimorfismos en el gen que codifica el factor derivado de c¨¦lulas de la estroma-1 (SDF-1) y la prote¨ªna quimioatractiva de monocitos-1 (MCP-1) se han relacionado con la presencia de arteriosclerosis subcl¨ªnica en pacientes infectados por el VIH-1 que reciben tratamiento antirretroviral(AU)</dc:description>
<dc:source>Enferm Infecc Microbiol Clin;26(supl.6): 18-23, mayo 2008.</dc:source>
<dc:identifier>ibc-60508</dc:identifier>
<dc:title xml:lang="es">Toxicogen¨¦tica del tratamiento antirretroviral (I): lipodistrofia, alteraciones metab¨®licas y arteriosclerosis</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d24718^s22057</dc:subject>
<dc:subject>^d11547</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d38362^s22045</dc:subject>
<dc:subject>^d1059^s22002</dc:subject>
<dc:subject>^d28903^s22002</dc:subject>
<dc:subject>^d52277^s22079</dc:subject>
<dc:subject>^d38332^s22020</dc:subject>
<dc:subject>^d50514^s22036</dc:subject>
<dc:subject>^d37260^s22033</dc:subject>
<dc:subject>^d1166^s22036</dc:subject>
<dc:subject>^d29591^s22079</dc:subject>
<dc:subject>^d32175^s22002</dc:subject>
<dc:subject>^d7426^s22033</dc:subject>
<dc:type>article</dc:type>
<dc:date>200805</dc:date>
</metadata>
</record>
</ibecs-document>
